These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10704681)

  • 1. Alterations of P19ARF in rodent hepatoma cell lines but not in human primary liver cancer.
    Laes J; Parada LA; Johansson B; Levan G; Szpirer C; Szpirer J
    Cancer Genet Cytogenet; 2000 Mar; 117(2):118-24. PubMed ID: 10704681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis.
    Herzog CR; Noh S; Lantry LE; Guan KL; You M
    Mol Carcinog; 1999 Jun; 25(2):92-8. PubMed ID: 10365910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p19Arf inhibits aggressive progression of H-ras-driven hepatocellular carcinoma.
    Kopanja D; Huang S; Al Raheed MRH; Guzman G; Raychaudhuri P
    Carcinogenesis; 2018 Mar; 39(3):318-326. PubMed ID: 29228217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica.
    Sherburn TE; Gale JM; Ley RD
    DNA Cell Biol; 1998 Nov; 17(11):975-81. PubMed ID: 9839807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16 is a major inactivation target in hepatocellular carcinoma.
    Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
    Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.
    Quelle DE; Cheng M; Ashmun RA; Sherr CJ
    Proc Natl Acad Sci U S A; 1997 Jan; 94(2):669-73. PubMed ID: 9012842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
    Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
    Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of p16INK4 in hepatocellular carcinoma.
    Hui AM; Sakamoto M; Kanai Y; Ino Y; Gotoh M; Yokota J; Hirohashi S
    Hepatology; 1996 Sep; 24(3):575-9. PubMed ID: 8781327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma.
    Piao Z; Park C; Lee JS; Yang CH; Choi KY; Kim H
    Cancer Lett; 1998 Jan; 122(1-2):201-7. PubMed ID: 9464511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
    Kamijo T; Zindy F; Roussel MF; Quelle DE; Downing JR; Ashmun RA; Grosveld G; Sherr CJ
    Cell; 1997 Nov; 91(5):649-59. PubMed ID: 9393858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
    Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
    Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties.
    Calabrò V; Parisi T; Di Cristofano A; La Mantia G
    Oncogene; 1999 Mar; 18(12):2157-62. PubMed ID: 10321741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alternative protein p19ARF: a genuine tumor suppressor gene].
    Larsen CJ
    Bull Cancer; 1998 Apr; 85(4):304-6. PubMed ID: 9752293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa.
    Trzeciak L; Hennig E; Kolodziejski J; Nowacki M; Ostrowski J
    Cancer Lett; 2001 Feb; 163(1):17-23. PubMed ID: 11163104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.
    Vonlanthen S; Heighway J; Altermatt HJ; Gugger M; Kappeler A; Borner MM; van Lohuizen M; Betticher DC
    Br J Cancer; 2001 May; 84(10):1372-6. PubMed ID: 11355949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
    Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
    Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.